Adamas Pharmaceuticals reported 21.97M in Sales Revenues for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Abbvie ABBV:US $ 13959M 949M
Acadia Pharmaceuticals ACAD:US $ 115.22M 8.67M
Acorda Therapeutics ACOR:US $ 31.78M 2.92M
Adamas Pharmaceuticals ADMS:US 21.97M 2.66M
Aerie Pharmaceuticals AERI:US $ 27.18M 4.22M
Aptinyx Inc APTX:US $ 0 1000K
Biocryst Pharmaceuticals BCRX:US $ 49.96M 30.9M
Flexion Therapeutics FLXN:US $ 28.17M 3.59M
Glaxosmithkline GSK:US $ 8092M 674M
GlaxoSmithKline GSK:LN 8092M 674M
Gw Pharmaceuticals GWPH:US $ 152.47M 4.24M
Heron Therapeutics HRTX:US $ 22.44M 2.42M
Intra Cellular Therapies ITCI:US $ 20.05M 4.17M
Marinus Pharmaceuticals MRNS:US 1.9M 99K
Merk MRK:US $ 11402M 678M
Neurocrine Biosciences NBIX:US $ 288.9M 52.3M
Novartis NOVN:VX SF 13294M 600M
Omeros OMER:US $ 28.82M 7.76M
Prothena PRTA:US 60.07M 59.91M
Revance Therapeutics RVNC:US $ 18.8M 5.5M
Teva Pharmaceutical TEVA:IT 3.91B 72M
Zogenix ZGNX:US $ 18.79M 5.11M